Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is N/A as of Tuesday, October 6, 2026.
GROSS MARGIN
N/A
Market Cap
$992.21M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$992.49M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
50.00%
5Y Avg
50.00%
Market Cap
$988.17M
Gross Margin
97.19%
TTM Avg
61.28%
3Y Avg
80.64%
5Y Avg
87.09%
Market Cap
$1.01B
Gross Margin
79.71%
TTM Avg
80.13%
3Y Avg
81.57%
5Y Avg
-49.18%
Market Cap
$1.02B
Gross Margin
53.74%
TTM Avg
53.23%
3Y Avg
56.54%
5Y Avg
58.23%
Market Cap
$1.03B
Gross Margin
11.80%
TTM Avg
10.80%
3Y Avg
10.72%
5Y Avg
10.72%
Market Cap
$1.04B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
16.67%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $996.75M | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $992.21M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aktis Oncology, Inc. (AKTS)vs › | $992.49M | 100.00% | 100.00% | 50.00% | 50.00% |
| MeiraGTx Holdings plc (MGTX)vs › | $988.17M | 97.19% | 61.28% | 80.64% | 87.09% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.01B | 79.71% | 80.13% | 81.57% | -49.18% |
| Immatics N.V. (IMTX)vs › | $1.01B | 100.00% | 100.00% | 100.00% | 64.23% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.02B | 53.74% | 53.23% | 56.54% | 58.23% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | 11.80% | 10.80% | 10.72% | 10.72% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.04B | 0.00% | 0.00% | 0.00% | 16.67% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.05B | 77.26% | 80.62% | 79.35% | 80.86% |
Gross Margin
N/A
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
